

Page 21, lines 27, to page 27, line 6, please replace the paragraph with the following paragraph:

4
A
--The sequence of human SP-C (SEQ ID NO: 13) is taken from Johansson, J., et al. (1988) FEBS Lett. **232**, 61-64 and that of SP-C(Leu) (SEQ ID NO: 14) from Nilsson, G., et al. (1999) Eur. J. Biochem, 255, 116-124). SP-C(LKS) (SEQ ID NO: 7) is based on the primary structure of SP-C but all Val residues at the positions 16-28 with the exception of position 17 are replaced with Leu residues, Lys residues have been introduced at positions 17,22, and 27, and the palmitoylated Cys at positions 5 and 6 are replaced with Ser.--

IN THE CLAIMS

Please amend the claims as follows:

09926009 "121101"
TOT2T" 60892660
3
--1. (Twice Amended) A SP-C analog having general formula (I) (SEQ ID NO:1), according to one-letter amino acid code:



wherein:

X is an amino acid selected from the group consisting of I, L, Nle (norleucine);

B is an amino acid selected from the group consisting of K, W, F, Y, Ornithine;

Z is S and can be optionally linked via ester or thio-ester bonds with acyl group containing 12-22 carbon atoms;

a is an integer from 1 to 19;

b is an integer from 1 to 19;

c is an integer from 1 to 21;

d is an integer from 0 to 20;

e is 0 or 1;

f is 0 or 1;

n is 0 or 1;

m is 0 or 1,

with the following conditions:

$n + m > 0$;

$f \geq e$;

$(X_aB)(X_bB)_n(X_cB)_mX_d$ is a sequence having a maximum of 22 amino acids.

2. (Amended) SP-C analogues according to claim 1, having formula (Ia) (SEQ ID

NO:2)

(Ia) FGIPSSPVHLKRX₄BX₄BX₄BXGALLMGL

3. (Amended) SP-C analogues according to claim 1, having formula (Ib) (SEQ ID

NO:3)

(Ib) FGIPSSPVHLKRX₅BX₅BX₄GALLMGL

4. (Amended) SP-C analogues according to claim 1, having formula (Ic) (SEQ ID

NO:4)

(Ic) FGIPSSPVHLKRX₄BX₁₁GALLMGL

5. (Amended) SP-C analogues according to claim 1, having formula (Id) (SEQ ID

NO:5)